The Use of Antibodies against Synthetic Peptides for Studying the EBV Nuclear Antigen
Five peptides corresponding to amino acid sequences predicted from the BamHI K fragment of the EBV genome have been synthesized (Table 1). The antisera raised against peptide no. 107, a copolymer of alanine and glycine deduced from the third internal repeat (IR3) sequence, gave brilliant nuclear staining in the anticomplement immunof1ourescence assay (AC IF) on eight EBV-carrying lines (Figure 1a),whereas five EBV-negative lines were not stained (Table 2). The nuclear staining was competed out by addition of the synthetic peptide (Figure 1b). 19 out of 21 EBNA-positive sera reacted with the synthetic peptide in an ELISA test, whereas EBV- negative sera did not react or gave very weak reactions (Figure 2). The 19 EBNA-positive sera that reacted with the peptide were all healthy donor sera whereas the 3 EBNA-positive sera that failed to react were Burkitt lymphoma (BL) patient sera.In a later series of experiments 34 EBNA-positive healthy donor sera were all found to react with the synthetic peptide, whereas out of 48 BL sera 19 did not have antibodies to this peptide (not shown).
KeywordsSynthetic Peptide ELISA Test Burkitt Lymphoma Raji Cell Anti Body
Unable to display preview. Download preview PDF.
- Dillner, J., Kallin, B., Ehlin, B., Timar, L and Klein, G. Int. J. Cancer in press.Google Scholar